Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Sections
MicroRNA in Health and Tumor
share announcement

MicroRNA in Health and Tumor

A topical collection in Biomedicines (ISSN 2227-9059). This collection belongs to the section "Immunology and Immunotherapy".

Viewed by 8462

Editor

Dr. Francesca Lovat

E-Mail Website
Collection Editor
Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
Interests: tumors; cancer research; cell biology; cancer diagnostics; cancer genetics; molecular biology; mouse model
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

MicroRNAs (miRNAs), short non-coding RNA, are involved in gene regulation, especially at the post-transcriptional level, and play a key role in a wide number of biological processes including differentiation, development, inflammation, immune response, drug resistance, and are usually dysregulated in many types of cancer. Moreover, miRNAs are differentially expressed in tumors compared to normal human tissues. Some of these altered miRNAs are overexpressed and known as oncomiR, which quicken tumor development, progression, dissemination. Contrarily, those that are downregulated in cancer patients are known as tumor suppressors. MiRNAs are also studied as biomarkers in clinical diagnosis and prognosis as well as indicator of treatment outcome and can be secreted as active molecule by different cell types. These “circulating miRNAs” are detected in various body fluids, including peripheral blood, saliva, urine, breast milk and represent specific, sensitive, and easy-to-detect biomarkers for clinical diagnosis or prognosis in cancers. Therefore, the accurate analysis of miRNAs expression and regulation from cancer patients might be a useful tool to develop personalized medicine in the future.

This Topical Collection aims to focus on the role of miRNAs in controlling pivotal biological mechanisms that lead to oncogenic transformation, including tumor formation, growth and dissemination, therapy resistance, as well as diagnostic and prognostic significance in different cancer subtypes. Original research manuscripts and comprehensive reviews are both welcomed for this call.

Dr. Francesca Lovat
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microRNAs
  • solid tumor
  • hematologic malignancies
  • cellular pathways
  • developmental pathways
  • gene expression
  • cancer genetic
  • liquid biopsy
  • biomarkers
  • mouse model
  • drug resistance

Published Papers (3 papers)

Download All Papers

2023

Jump to: 2022

16 pages, 1449 KiB  
Review
miRNAs’ Cross-Involvement in Skin Allergies: A New Horizon for the Pathogenesis, Diagnosis and Therapy of Atopic Dermatitis, Allergic Contact Dermatitis and Chronic Spontaneous Urticaria
by Raffaele Brancaccio, Giuseppe Murdaca, Rossella Casella, Teresa Loverre, Laura Bonzano, Eustachio Nettis and Sebastiano Gangemi
Biomedicines 2023, 11(5), 1266; https://doi.org/10.3390/biomedicines11051266 - 24 Apr 2023
Cited by 3 | Viewed by 2379
Abstract
Skin inflammation is a common underlying feature of atopic dermatitis, allergic contact dermatitis and chronic spontaneous urticaria. The pathogenetic mechanisms have not been fully elucidated. The purpose of this study was to examine whether miRNA, by regulating inflammatory mechanisms through the modulation of [...] Read more.
Skin inflammation is a common underlying feature of atopic dermatitis, allergic contact dermatitis and chronic spontaneous urticaria. The pathogenetic mechanisms have not been fully elucidated. The purpose of this study was to examine whether miRNA, by regulating inflammatory mechanisms through the modulation of innate and adaptive immune responses, could play a major role in the pathogenesis of these skin conditions. We conducted a narrative review using the Pubmed and Embase scientific databases and search engines to find the most relevant miRNAs related to the pathophysiology, severity and prognosis of skin conditions. The studies show that miRNAs are involved in the pathogenesis and regulation of atopic dermatitis and can reveal an atopic predisposition or indicate disease severity. In chronic spontaneous urticaria, different miRNAs which are over-expressed during urticaria exacerbations not only play a role in the possible response to therapy or remission, but also serve as a marker of chronic autoimmune urticaria and indicate associations with other autoimmune diseases. In allergic contact dermatitis, miRNAs are upregulated in inflammatory lesions and expressed during the sensitization phase of allergic response. Several miRNAs have been identified as potential biomarkers of these chronic skin conditions, but they are also possible therapeutic targets. Full article
►▼ Show Figures

Figure 1

2022

Jump to: 2023

20 pages, 1026 KiB  
Systematic Review
Urinary miRNAs as a Diagnostic Tool for Bladder Cancer: A Systematic Review
by Anna Maria Grimaldi, Cristina Lapucci, Marco Salvatore, Mariarosaria Incoronato and Maurizio Ferrari
Biomedicines 2022, 10(11), 2766; https://doi.org/10.3390/biomedicines10112766 - 31 Oct 2022
Cited by 10 | Viewed by 2358
Abstract
Bladder cancer is the 10th most common cancer type worldwide. Cystoscopy represents the gold standard for bladder cancer diagnosis, but this procedure is invasive and painful, hence the need to identify new biomarkers through noninvasive procedures. microRNAs (miRNAs) are considered to be promising [...] Read more.
Bladder cancer is the 10th most common cancer type worldwide. Cystoscopy represents the gold standard for bladder cancer diagnosis, but this procedure is invasive and painful, hence the need to identify new biomarkers through noninvasive procedures. microRNAs (miRNAs) are considered to be promising diagnostic molecules, because they are very stable in biological fluids (including urine) and easily detectable. This systematic review analyses the power of urine miRNAs as bladder cancer diagnostic markers. We conducted this systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. A total of 293 records related to miRNAs and their diagnostic significance in BC were retrieved from the PubMed and Embase databases. A systematic search of the literature was performed, and a total of 25 articles (N = 4054 participants) were identified and reviewed. Although many of the selected studies were of high scientific quality, the results proved to be quite heterogeneous, because we did not identify a univocal consensus for a specific miRNA signature but only isolated the signatures. We did not identify a univocal consensus for a specific diagnostic miRNA signature but only isolated the signatures, some of them with better diagnostic power compared to the others. Full article
►▼ Show Figures

Figure 1

17 pages, 905 KiB  
Review
Role of microRNAs in B-Cell Compartment: Development, Proliferation and Hematological Diseases
by Olívia Fonseca Souza and Ana Flavia Popi
Biomedicines 2022, 10(8), 2004; https://doi.org/10.3390/biomedicines10082004 - 18 Aug 2022
Cited by 10 | Viewed by 3105
Abstract
B-cell development is a very orchestrated pathway that involves several molecules, such as transcription factors, cytokines, microRNAs, and also different cells. All these components maintain the ideal microenvironment and control B-cell differentiation. MicroRNAs are small non-coding RNAs that bind to target mRNA to [...] Read more.
B-cell development is a very orchestrated pathway that involves several molecules, such as transcription factors, cytokines, microRNAs, and also different cells. All these components maintain the ideal microenvironment and control B-cell differentiation. MicroRNAs are small non-coding RNAs that bind to target mRNA to control gene expression. These molecules could circulate in the body in a free form, protein-bounded, or encapsulated into extracellular vesicles, such as exosomes. The comprehension of the role of microRNAs in the B-cell development was possible based on microRNA profile of each B-cell stage and functional studies. Herein, we report the knowledge about microRNAs in the B-cell the differentiation, proliferation, and also in hematological malignancies. Full article
►▼ Show Figures

Figure 1

Back to TopTop